Darifen ER7.5 mg

Darifen ER is indicated for the treatment of overactive bladder (OAB) in adults, with symptoms of:

• Urinary urgency
• Urinary frequency
• Urge incontinence (involuntary leakage of urine associated with a sudden, compelling urge to urinate)

This is an established, FDA-approved indication supported by randomized controlled clinical trials. Darifen ER is not indicated for stress incontinence or for lower urinary tract symptoms due to bladder outlet obstruction.

Each extended-release tablet contains Darifenacin (as darifenacin hydrobromide) as the active ingredient, commonly available in strengths of 7.5 mg and 15 mg. Inactive excipients typically include the tablet core and a controlled-release coating that regulates drug release over 24 hours; exact excipient composition varies by manufacturer.

Darifen ER is a third-generation, selective antimuscarinic (anticholinergic) agent developed specifically for the management of overactive bladder. Unlike older, non-selective anticholinergics, Darifen ER shows greater selectivity for the M3 muscarinic receptor subtype, which is the predominant receptor mediating bladder detrusor muscle contraction.

It is formulated as a once-daily, extended-release oral tablet that must be swallowed whole.

Mechanism of Action

Darifenacin is a selective antagonist of the M3 muscarinic acetylcholine receptor subtype. In the bladder, M3 receptors mediate acetylcholine-induced contraction of detrusor smooth muscle. By selectively blocking M3 receptors, Darifenacin reduces involuntary detrusor contractions, decreases urinary urgency and frequency, and reduces episodes of urge incontinence, while showing relatively less affinity for M1, M2, M4, and M5 receptor subtypes compared with non-selective anticholinergics.

Pharmacokinetics

Darifenacin is well absorbed after oral administration, with peak plasma concentrations reached approximately 7 hours after dosing with the extended-release formulation. It is extensively metabolized in the liver, primarily via CYP3A4 and CYP2D6 enzymes, and is highly protein bound (approximately 98%). The terminal elimination half-life is approximately 13-19 hours, supporting once-daily dosing. Metabolites are excreted mainly in urine and feces.

Darifen ER extended-release tablets should be swallowed whole with water, without crushing, chewing, or splitting. May be taken with or without food, at approximately the same time each day to maintain consistent drug levels.

The following are well-established, clinically significant interactions with Darifen ER:

• Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole, clarithromycin, ritonavir, nelfinavir): increase plasma concentrations of Darifen ER; the dose of Darifen ER should be limited to 7.5 mg once daily when co-administered.
• CYP2D6 substrates with a narrow therapeutic index (e.g., flecainide, thioridazine, certain tricyclic antidepressants): Darifen ER moderately inhibits CYP2D6 and may increase plasma levels of these drugs; monitor closely or adjust dose if co-administered.
• Other anticholinergic (antimuscarinic) drugs: concurrent use may produce additive anticholinergic effects such as dry mouth, constipation, and blurred vision.
• Drugs affecting GI motility (e.g., digoxin in some cases, or drugs requiring intact GI motility for absorption): use with caution due to the anticholinergic effect of Darifen ER on GI transit.

Inform your physician or pharmacist of all medicines, supplements, and herbal products you are taking before starting Darifen ER.

The most common side effects of Darifen ER, related to its anticholinergic mechanism, include:

• Dry mouth (very common)
• Constipation (common; counsel patients on adequate fluid intake and dietary fiber)
• Headache
• Dyspepsia (indigestion)
• Abdominal pain
• Dry eyes
• Blurred vision
• Urinary tract infection

Less commonly, more severe gastrointestinal effects such as fecal impaction have been reported, particularly at higher doses or in patients with pre-existing GI conditions. See Precautions and Warnings for further detail.

Pregnancy: There are limited data on the use of Darifen ER in pregnant women. Darifen ER should be used during pregnancy only if clearly needed and the potential benefit justifies the potential risk to the fetus. Consult a physician before use if pregnant or planning pregnancy.

Lactation: It is not known whether Darifen ER is excreted in human breast milk. Because many drugs are excreted in breast milk, caution should be exercised and a physician consulted before use while breastfeeding, weighing the benefit of treatment against potential infant exposure.

Use Darifen ER with caution in the following situations:

• Anticholinergic effects: dry mouth and constipation are common; counsel patients on adequate fluid intake and dietary fiber. Severe GI effects, including fecal impaction, have been reported, particularly at higher doses or in patients with pre-existing GI conditions.
• Controlled narrow-angle glaucoma: use with caution and appropriate ophthalmologic monitoring (uncontrolled narrow-angle glaucoma is an absolute contraindication; see Contraindications).
• Bladder outlet obstruction: risk of urinary retention; use with caution, particularly in men with symptomatic benign prostatic hyperplasia (BPH).
• Reduced gastrointestinal motility conditions (e.g., myasthenia gravis, ulcerative colitis, GI obstructive disorders): use with caution given the anticholinergic mechanism.
• Hepatic impairment: dose adjustment required in moderate impairment; avoid in severe impairment (see Dosage and Administration).
• CNS anticholinergic effects: confusion and other CNS effects may occur, particularly in elderly patients; use with caution in this population.
• Drug interactions: significant CYP3A4- and CYP2D6-mediated interactions may require dose adjustment with certain concurrent medications (see Interactions).
• Angioedema of the face, lips, tongue, and/or larynx has been reported rarely; discontinue immediately and seek medical attention if it occurs.

Overdose with Darifen ER may cause exaggerated anticholinergic effects, such as severe dry mouth, blurred vision, urinary retention, constipation, and central nervous system effects (e.g., agitation, confusion). In case of suspected overdose, seek immediate medical attention or contact a poison control center. Treatment is supportive and symptomatic; there is no specific antidote. Activated charcoal or gastric lavage may be considered by a physician if the overdose is recent, and cardiac monitoring may be advised. Do not attempt to manage an overdose at home without medical guidance.

Store at room temperature (below 30°C), away from light and moisture. Keep out of reach of children.

Pediatric Use

Safety and efficacy of Darifen ER have not been established in children. Its use in the pediatric population is not recommended.

Elderly (Geriatric) Use

No overall dose adjustment based on age alone is required in elderly patients; however, this population may be more susceptible to anticholinergic CNS effects such as confusion, so Darifen ER should be used with caution and patients monitored closely.

Hepatic Impairment

Dose should not exceed 7.5 mg once daily in moderate hepatic impairment (Child-Pugh B); use is not recommended in severe hepatic impairment (Child-Pugh C).

Renal Impairment

No specific dose adjustment is generally required, though caution is advised in severe renal impairment.

Duration of treatment with Darifen ER is individualized based on symptom response and physician assessment. Clinical benefit is usually assessed within 2 to 4 weeks of starting therapy or after a dose increase. Darifen ER is generally used as a longer-term, chronic therapy for overactive bladder, with periodic physician review to confirm continued need and tolerability.

Darifenacin is classified as an antimuscarinic (anticholinergic) agent, specifically a selective M3 muscarinic receptor antagonist used in the urology/urogynecology drug class for overactive bladder.

Darifenacin selectively binds to and blocks M3 muscarinic acetylcholine receptors located on bladder detrusor smooth muscle, which are the predominant receptor subtype mediating acetylcholine-induced bladder contraction. By antagonizing M3 receptors, Darifenacin reduces involuntary detrusor muscle contractions, thereby decreasing urinary urgency, frequency, and episodes of urge incontinence associated with overactive bladder.

C

Safety and efficacy of Darifen ER have not been established in pediatric patients, and its use is not recommended in children. Darifen ER is indicated only for adult patients with overactive bladder.